Capsovision To Participate In Upcoming Investor Conferences
H.C. Wainwright 28th Annual Global Investment Conference (September 14-16 in New York City)
- Format: On-demand Company Presentation and 1x1 Investor Meetings Date/Time:
- On-demand Company Presentation – Friday, September 11, 2026, beginning at 7:00 am ET 1x1 Investor Meetings – Monday, September 14, 2026
5th Annual ROTH Healthcare Opportunities Conference (September 29 in New York City)
- Format: 1x1 Investor Meetings Date/Time: Tuesday, September 29, 2026
The on-demand presentation will be available on the Events page in the investor relations section of the company's website for 90 days. If you are interested in arranging a one-on-one meeting with CapsoVision's management team at the conferences, please contact your respective H.C. Wainwright and Roth representatives or reach out to the company directly at ....
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company's next pipeline product, CapsoCam ColonTM with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit .
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
...
Media Contact
Leslie Strickler and Paul Spicer
Être Communications
... | (804) 240-0807
... | (804) 503-9231

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment